Trial Profile
Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Ciclosporin; Ciclosporin; Methotrexate; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Jul 2020 Primary endpoint (Incidence of grade 2-4 aGVHD on day 100.) has been met as per result published in the Journal of Clinical Oncology
- 10 Jul 2020 Results published in the Journal of Clinical Oncology
- 10 Jul 2020 Status changed to completed as per result published in the Journal of Clinical Oncology